Adaptive Biotechnologies Q3 revenue $47.8M (+21% YoY); narrows FY2022 revenue guidance to $185-190M

Adaptive Biotechnologies Corp

2022-Q3 EPS reported -$1.12 revenue$130,110,000

Q3 2022 revenue $47.8M vs $39.5M in Q3 2021 (+21%); clonoSEQ test volume up 52% YoY.
Immune Medicine revenue $27.9M (+18% YoY); MRD revenue $20.0M (+26% YoY).
Net loss improved to $45.3M from $56.0M; adjusted EBITDA loss $25.9M vs $41.1M.
FY2022 revenue guidance narrowed to $185-190M from $185-195M; opex now expected below $400M.
Signed $250M non-dilutive royalty financing with OrbiMed; Epic partnership for clonoSEQ EMR integration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Adaptive Biotechnologies Corp updated its the quarter ended September 30, 2022 guidance (reaffirmed).

Period: the quarter ended September 30, 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On November 3, 2022, Adaptive Biotechnologies Corporation (the “ Company ”) issued a press release regarding the Company’s financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0000950170-22-021886

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.